Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$5.79 - $8.6 $157,389 - $233,773
-27,183 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$6.5 - $10.53 $15,788 - $25,577
-2,429 Reduced 8.2%
27,183 $220,000
Q4 2020

Feb 16, 2021

BUY
$3.7 - $7.66 $109,564 - $226,827
29,612 New
29,612 $191,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Athanor Capital, LP Portfolio

Follow Athanor Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Athanor Capital, LP with notifications on news.